References
1. Spellberg B, Edwards J Jr., Ibrahim A. Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev 2005;18:556-69
2. ARTIS, W. M.; FOUNTAIN, J. A.; DECLCHER, H. K. & JONES, H. E. — A mechanism of susceptibility to mucormycosis in diabetic ketoacidosis: Transferrin and iron availability. Diabetes 31: 1108-1114, 1983.
3. Ribes JA, Vanover-Sams CL, Baker DJ. Zygomycetes in human disease. Clin Microbiol Rev 2000; 13:236-301.
4. Skiada A, Rigopoulos D, Larios G, Petrikkos G, Katsambas A. Global epidemiology of cutaneous zygomycosis. Clin Dermatol 2012;30:628-32.
5. Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA, Schaufele RL et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005; 41: 634-53
6. Kontoyiannis, DP and Lewis, RE. Agents of mucormycosis and entomophth-oramycosis. in: GL Mandell, JE Bennett, R Dolin (Eds.) Principles and practice of infectious diseases. 7th edn. Churchill Livingstone/Elsevier, Philadelphia,PA; 2009
7. Hibbett, DS, Binder, M, Bischoff, JF et al. A higher-level phylogenetic classification of the Fungi.Mycol Res. 2007; 111: 509–547
8. Ribes, JA, Vanover-Sams, CL, and Baker, DJ. Zygomycetes in human disease. Clin Microbiol Rev.2000; 13: 236–301
9. Pappas, PG, Alexander, BD, Andes, DR et al. Invasive fungal infections among organ transplant recipients: results of the Transplant- Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis. 2010;50
10. Chakrabarti, A, Das, A, Sharma, A et al. Ten years' experience in zygomycosis at a tertiary care centre in India. J Infect. 2001; 42: 261–266
11. Diwakar, A, Dewan, RK, Chowdhary, A, Randhawa, HS, Khanna, G, and Gaur, SN. Zygomycosis—a case report and overview of the disease in India. Mycoses. 2007; 50: 247–254
12. Meis, JF and Chakrabarti, A. Changing epidemiology of an emerging infection: zygomycosis. Clin Microbiol Infect. 2009; 15: 10–14
13. Antoniadou, A. Outbreaks of zygomycosis in hospitals. Clin Microbiol Infect. 2009; 15: 55–59
14. Chamilos, G, Marom, EM, Lewis, RE, Lionakis, MS, and Kontoyiannis, DP. Predictors of pulmonary zygomycosis versus invasive pulmonary aspergillosis in patients with cancer. Clin Infect Dis. 2005; 41:60–66
15. Kalpatti, R, Peters, B, Kane, I et al. Safety and efficacy of high dose intravenous desferrioxamine for reduction of iron overload in sickle cell disease. Pediatr Blood Cancer. 2010; 55: 1338–1342
16. Trifilio, SM, Bennett, CL, Yarnold, PR et al. Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy. Bone Marrow Transplant. 2007; 39: 425–429
17. Tleyjeh, IM, Kashour, T, Hakim, FA et al. Statins for the prevention and treatment of infections: a systematic review and meta-analysis. Arch Intern Med. 2009; 169: 1658–1667
18. James, William D.; Berger, Timothy G.; et al. (2006). Andrews' Diseases of the Skin: clinical Dermatology.
19. Lee F.Y.; Mossad S.B.; Adal K.A. (1999). "Pulmonary mucormycosis: the last 30 years". Arch Intern Med 159: 1301–9.
20. Spellberg B, Edwards J, Ibrahim A (2005). "Novel perspectives on mucormycosis: pathophysiology, presentation, and management". Clin. Microbiol. Rev. 18 (3): 556–69.
21. Choo JY, Park CM, Lee HJ et-al. Sequential morphological changes in follow-up CT of pulmonary mucormycosis. Diagn Interv Radiol. 2013;20 (1): 42-6.
22. Bennett JE, Dolin R, Blaser MJ. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases: Expert Consult Premium Edition - Enhanced Online Features and Print, 8e
DOI: https://dx.doi.org/10.18535/jmscr/v5i6.81
